Tadalafil Tablet
Product Images NDC 71610-909

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-909). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0909 36)

FDA Label Image

Aphena (Aphena)

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This is a description of blood pressure measurements taken in standing and supine positions. It includes readings for both diastolic and systolic blood pressure. Additionally, there are time markers provided, indicating a monitoring or tracking of blood pressure changes over time.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This text provides information on a medication regimen involving Tadalafil 20 mg and doxazosin 8 mg for managing systolic blood pressure. The data seems to illustrate the effect of the medication on blood pressure levels.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

This text provides information related to the impact of different medication doses on systolic blood pressure at various time points. The study mentions the administration of 20 mg tadalafil and 8 mg doxazosin at 08:00, as well as placebo and 8 mg doxazosin at the same time. Additionally, it discusses the administration of 20 mg tadalafil at 20:00 and 8 mg doxazosin at 08:00, along with placebo and 8 mg doxazosin at 08:00. The data suggests a comparison of systolic blood pressure under these different conditions over time.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

This information appears to be related to a study or clinical trial comparing the effectiveness of Tadalafil tablets (5 mg) versus a placebo in treating a certain condition. The data includes the change from baseline in the IPSS Total Score over a duration of treatment of 12 weeks. The results suggest a statistically significant difference (*p<0.001) between the two treatment groups.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

This is a table showing the effectiveness of Tadalafil tablets 5 mg compared to a placebo over a duration of treatment in weeks. The results suggest a statistically significant difference between the two groups.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

LS Mean Change from Baseline for TadalafilFinasteride and PlaceboFinasteride. The text mentions "Least Squares Treatment Difference" which may be referring to a statistical analysis for comparing the two treatments. The data seems to be related to comparing changes over time for these treatments in a study or experiment.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text appears to be presenting data related to a study involving Tadalafil tablets at a 5mg dosage compared to a placebo. The information likely includes statistical significance indicated by "p<0.01" and a graph showing the duration of treatment in weeks.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.